Johnson & Johnson Vision Care Second Quarter U.S. Sales Flat

By

NEW BRUNSWICK, N.J.—U.S. sales for the vision care division of Johnson & Johnson (NYSE: JNJ) remained flat at $262 million for the second quarter of 2014 when compared with an equal amount of sales for the same period for 2013, according to the 2014 second quarter financial results released yesterday by the company. International vision care sales, excluding those in the U.S., were down almost 5 percent from $468 million for the second quarter of 2013 to $445 million in Q2 2014. Overall worldwide sales for the vision care division during the second quarter of 2014, including the U.S., were down 3.2 percent from $730 million in the second quarter of 2013 to $707 million in Q2 2014.
 
For the first half of 2014, U.S. sales for the vision care division were up slightly (0.9 percent) from $543 million in 2013 to $548 million for the same period in 2014. International vision care sales, excluding the U.S., were down 0.8 percent from $927 million for the first six months of 2013 to $920 million for the same period in 2014. Overall worldwide vision care sales for Johnson & Johnson for the first half of 2014, including the U.S., were almost flat (down only 0.1 percent), from $1,470 million during the first six months of 2013 to $1,468 million during the same period of 2014.
 
The company’s overall sales of $19.5 billion for the second quarter of 2014 represent an increase of 9.1 percent when compared to the second quarter of 2013. Domestic sales increased 14.9 percent to $9.1 billion, and international sales (excluding the U.S.) increased 4.4 percent to $10.4 billion. For the first half of 2014, overall sales increased 6.3 percent to $37.6 billion, domestic sales were up 8.5 percent to $17.4 billion, and international sales (excluding the U.S.) increased 4.4 percent to $20.3 billion.